0000891293-16-000113.txt : 20160304 0000891293-16-000113.hdr.sgml : 20160304 20160304183033 ACCESSION NUMBER: 0000891293-16-000113 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160304 FILED AS OF DATE: 20160304 DATE AS OF CHANGE: 20160304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Plunkett Matthew CENTRAL INDEX KEY: 0001557551 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12465 FILM NUMBER: 161486531 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE, SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2016-03-04 0 0000891293 CTI BIOPHARMA CORP ctic 0001557551 Plunkett Matthew 3101 WESTERN AVENUE, SUITE 600 SEATTLE WA 98121 0 1 0 0 EVP, Chief Business Officer Common Stock 2016-03-04 4 S 0 1300 0.585 D 598784 D Common Stock 2016-03-04 4 S 0 400 0.586 D 598384 D Common Stock 2016-03-04 4 S 0 636 0.587 D 597748 D Common Stock 2016-03-04 4 S 0 1500 0.588 D 596248 D Common Stock 2016-03-04 4 S 0 844 0.589 D 595404 D Common Stock 2016-03-04 4 S 0 700 0.59 D 594704 D Common Stock 2016-03-04 4 S 0 700 0.591 D 594004 D Common Stock 2016-03-04 4 S 0 200 0.592 D 593804 D Common Stock 2016-03-04 4 S 0 1100 0.593 D 592704 D Common Stock 2016-03-04 4 S 0 500 0.594 D 592204 D Common Stock 2016-03-04 4 S 0 1220 0.595 D 590984 D Common Stock 2016-03-04 4 S 0 900 0.596 D 590084 D The sale was effected pursuant to a Rule 10b5-1 trading plan. By: Louis A. Bianco, Attorney-in-fact For: Matthew J. Plunkett 2016-03-04